Incidence rates and clinical characteristics of primary gastrointestinal non-Hodgkin lymphoma: a population study.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
3
1
2020
medline:
29
6
2021
entrez:
3
1
2020
Statut:
ppublish
Résumé
After the rise of lymphoma incidence in the 1990's, there is a paucity of epidemiologic studies describing the characteristics of primary gastrointestinal non-Hodgkin's lymphoma (PGIL). This epidemiologic survey aims to identify recent trends in PGIL. A retrospective, population-based study describing adult patients with PGIL in the Israeli Negev region between 1998 and 2013. 131 patients were diagnosed with PGIL, representing an annual incidence rate of 22.42/100,000, compared to 35.87/100,000 in the overall Israeli population. Both incidence rates did not significantly change during the study period. The median age was 66 years, and the most common presentation was in the stomach (49.6%) and oral cavity (18.3%). Histologically, diffuse large B cell lymphoma (DLBCL) was predominant (55.0%). Most patients (66.4%) had early stage disease. Only T-cell lymphoma showed a male predominance (14.7% versus 5.4%, P=0.008). Fifty patients (44.2%) had H. pylori testing, and 35 (70.0%) were positive. Of these, 91.4% received eradication treatment, and 57.1% were negative thereafter.Most patients received CHOP or RCHOP protocols (16.0% and 48.1%, respectively). Complete response was achieved in 53.4%. Median follow-up was 48 months, and 62 patients (47.3%) died during the study period. Liver involvement had a worse prognosis, (33.0% 5-year survival) compared to upper and lower GI disease(70.5% and 46.8% respectively, P=0.003 for the comparison between liver and other locations). T-cell lymphoma had worse survival (11 months vs. not reached, P=0.003). This study demonstrates the incidence, and clinical characteristics of PGIL in the Negev region. It is important to identify disease characteristics, thus facilitating better disease detection and prognostication.
Sections du résumé
BACKGROUND & AIMS
After the rise of lymphoma incidence in the 1990's, there is a paucity of epidemiologic studies describing the characteristics of primary gastrointestinal non-Hodgkin's lymphoma (PGIL). This epidemiologic survey aims to identify recent trends in PGIL.
METHODS
A retrospective, population-based study describing adult patients with PGIL in the Israeli Negev region between 1998 and 2013.
RESULTS
131 patients were diagnosed with PGIL, representing an annual incidence rate of 22.42/100,000, compared to 35.87/100,000 in the overall Israeli population. Both incidence rates did not significantly change during the study period. The median age was 66 years, and the most common presentation was in the stomach (49.6%) and oral cavity (18.3%). Histologically, diffuse large B cell lymphoma (DLBCL) was predominant (55.0%). Most patients (66.4%) had early stage disease. Only T-cell lymphoma showed a male predominance (14.7% versus 5.4%, P=0.008). Fifty patients (44.2%) had H. pylori testing, and 35 (70.0%) were positive. Of these, 91.4% received eradication treatment, and 57.1% were negative thereafter.Most patients received CHOP or RCHOP protocols (16.0% and 48.1%, respectively). Complete response was achieved in 53.4%. Median follow-up was 48 months, and 62 patients (47.3%) died during the study period. Liver involvement had a worse prognosis, (33.0% 5-year survival) compared to upper and lower GI disease(70.5% and 46.8% respectively, P=0.003 for the comparison between liver and other locations). T-cell lymphoma had worse survival (11 months vs. not reached, P=0.003).
CONCLUSIONS
This study demonstrates the incidence, and clinical characteristics of PGIL in the Negev region. It is important to identify disease characteristics, thus facilitating better disease detection and prognostication.
Identifiants
pubmed: 31895909
doi: 10.1097/MEG.0000000000001651
pii: 00042737-202005000-00005
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-574Références
Li M, Zhang S, Gu F, Xiao W, Yao J, Chao K, et al. Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from south china. Int J Clin Exp Pathol. 2014; 7:2718–2728
Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT Jr. Malignant lymphoma. 1. The histology and staging of 473 patients at the national cancer institute. Cancer. 1982; 50:2699–2707
Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011; 17:697–707
Shirsat HS, Vaiphei K. Primary gastrointestinal lymphomas - a study of 81 cases from a Tertiary Healthcare Centre. Indian J Cancer. 2014; 51:290–292
Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al.; German Multicenter Study Group. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German multicenter study GIT NHL 01/92. J Clin Oncol. 2001; 19:3861–3873
Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic cooperative oncology group study (hecog). Leuk Lymphoma. 2006; 47:2140–2146
Devaney K, Jaffe ES. The surgical pathology of gastrointestinal Hodgkin’s disease. Am J Clin Pathol. 1991; 95:794–801
Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer. 2008; 123:2658–2663
Liu S, Semenciw R, Mao Y. Increasing incidence of non-Hodgkin’s lymphoma in Canada, 1970-1996: age-period-cohort analysis. Hematol Oncol. 2003; 21:57–66
Howell JM, Auer-Grzesiak I, Zhang J, Andrews CN, Stewart D, Urbanski SJ. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can J Gastroenterol. 2012; 26:452–456
Halme L, Mecklin JP, Juhola M, Krees R, Palmu A. Primary gastrointestinal non-Hodgkin’s lymphoma. A population based study in central Finland in 1975-1993. Acta Oncol. 1997; 36:69–74
Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015; 372:1441–1452
Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, et al.; CESAME Study Group. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18:2063–2071
Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015; 13:847–58.e4; quiz e48
Lewis RB, Mehrotra AK, Rodríguez P, Manning MA, Levine MS. From the radiologic pathology archives: gastrointestinal lymphoma: radiologic and pathologic findings. Radiographics. 2014; 34:1934–1953
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32:3059–3068
Ruskoné-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, De Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut. 2003; 52:912–913
Rohatiner A, d’Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994; 5:397–400
Chang S, Shi X, Xu Z, Liu Q. TNM staging system may be superior to Lugano and Ann Arbor systems in predicting the overall survival of patients with primary gastrointestinal lymphoma. J Buon. 2015; 20:812–819
Hwang HS, Yoon DH, Suh C, Park CS, Huh J. Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems. J Korean Med Sci. 2014; 29:53–60
Swerdlow S, Campo E, Harris NL, Jaffe E, Pileri S, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer. 2008, Washington, DC: World Health Organization
Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the united states from 1978 through 1995. J Natl Cancer Inst. 2000; 92:1240–1251
Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin’s lymphoma incidence in the united states from 1973 through 1998. J Natl Cancer Inst. 2002; 94:1204–1210
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108
Müller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005; 84:1–12
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by world health organization subtypes. CA Cancer J Clin. 2016; 66:443–459
Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002; 95:1504–1510
Hartge P, Devesa SS. Quantification of the impact of known risk factors on time trends in non-Hodgkin’s lymphoma incidence. Cancer Res. 1992; 52:5566s–5569s
Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Flynn S, et al. Hair-coloring product use and risk of non-Hodgkin’s lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol. 2004; 159:148–154
Arora N, Manipadam MT, Pulimood A, Ramakrishna BS, Chacko A, Kurian SS, Nair S. Gastrointestinal lymphomas: pattern of distribution and histological subtypes: 10 years experience in a tertiary centre in south India. Indian J Pathol Microbiol. 2011; 54:712–719
Kim SJ, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, et al. Multicenter retrospective analysis of 581 patients with primary intestinal non-Hodgkin lymphoma from the consortium for improving survival of lymphoma (CISL). BMC Cancer. 2011; 11:321